- Home
- IOBT
IOBT
IO Biotech Inc.
as 07-26-2024 4:00pm EST
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
| Founded: | 2014 | Country: | Denmark |
| Employees: | N/A | City: | COPENHAGEN |
| Market Cap: | 77.7M | IPO Year: | 2021 |
| Target Price: | $9.67 | AVG Volume (30 days): | 176.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.82 - $2.18 | Next Earning Date: | 08-09-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of IO Biotech Inc. (IOBT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Novo Holdings A/S | IOBT | 10% Owner | May 10 '24 | Sell | $1.22 | 658,809 | $802,495.24 | 4,429,449 | SEC Form 4 |
| Novo Holdings A/S | IOBT | 10% Owner | Feb 9 '24 | Sell | $1.50 | 658,809 | $988,411.14 | 5,088,258 | SEC Form 4 |
| Burkavage Brian | IOBT | Chief Accounting Officer | Nov 21 '23 | Buy | $0.99 | 5,000 | $4,950.00 | 6,500 | SEC Form 4 |
| Burkavage Brian | IOBT | Chief Accounting Officer | Nov 21 '23 | Buy | $1.04 | 5,000 | $5,175.00 | 11,500 | SEC Form 4 |
Latest IO Biotech Inc. News
IOBT Breaking Stock News: Dive into IOBT Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024
Simply Wall St.
6 days ago
IO Biotech, Inc.'s (NASDAQ:IOBT) market cap touched US$104m last week, benefiting both private equity firms who own 59% as well as institutions
Simply Wall St.
2 months ago
Will IO Biotech (NASDAQ:IOBT) Spend Its Cash Wisely?
GlobeNewswire
2 months ago
IO Biotech to Present at Jefferies Global Healthcare Conference
GlobeNewswire
2 months ago
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
GlobeNewswire
3 months ago
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
3 months ago
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
GlobeNewswire
4 months ago
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103
Compare IOBT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IOBT IO Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.